公开(公告)号：US20240358691A1

公开(公告)日：2024-10-31

申请号：US18537481

申请日：2023-12-12

Applicant: Akebia Therapeutics, Inc.

Inventor： Richard Masaru Kawamoto ,  Shengde Wu ,  Artem G. Evdokimov ,  Kenneth D. Greis ,  Angelique Sun Boyer ,  Namal C. Warshakoon

IPC: A61K31/4418 ,  A61K31/4433 ,  C07C235/60 ,  C07C237/42 ,  C07C255/57 ,  C07D213/65 ,  C07D213/81 ,  C07D295/192 ,  C07D401/04 ,  C07D401/10 ,  C07D405/04 ,  C07D405/10 ,  C07D417/04

CPC classification number: A61K31/4418 ,  A61K31/4433 ,  C07C235/60 ,  C07C237/42 ,  C07C255/57 ,  C07D213/65 ,  C07D213/81 ,  C07D295/192 ,  C07D401/04 ,  C07D401/10 ,  C07D405/04 ,  C07D405/10 ,  C07D417/04 ,  Y02A50/30

Abstract: The present disclosure relates to HIF-la prolyl hydroxylase inhibitors, compositions which comprise the HIF-la prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

公开(公告)号：US12110279B2

公开(公告)日：2024-10-08

申请号：US17726323

申请日：2022-04-21

Applicant: Yuhan Corporation

Inventor： Hee Jae Tak ,  Eun Kyung Kim ,  Hyok Jun Cho ,  Cheol Hee Lim

IPC: C07D405/14 ,  C07D257/04 ,  C07D401/04 ,  C07D401/14 ,  C07D405/10 ,  C07D409/04 ,  C07D409/06 ,  C07D409/14 ,  C07D413/10 ,  C07D401/10

CPC classification number: C07D257/04 ,  C07D401/04 ,  C07D401/14 ,  C07D405/10 ,  C07D409/04 ,  C07D409/06 ,  C07D409/14 ,  C07D413/10 ,  C07D401/10

Abstract: The present technology provides triazolones, tetrazolones, and imidazolones, or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolones, tetrazolones, and imidazolones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20240324264A1

公开(公告)日：2024-09-26

申请号：US18669611

申请日：2024-05-21

Applicant: The University of Southern California ,  The Regents of the University of Michigan

Inventor： Mark E. Thompson ,  Abegail Tadle ,  Muazzam Idris ,  Karim El Roz ,  Daniel Sylvinson Muthiah Ravinson ,  Stephen R. Forrest ,  Chan Ho Soh

IPC: H10K50/11 ,  C07D233/58 ,  C07D401/10 ,  C09K11/06 ,  H10K50/125 ,  H10K85/30 ,  H10K85/60 ,  H10K101/00 ,  H10K101/10 ,  H10K101/30

CPC classification number: H10K50/11 ,  C07D233/58 ,  C07D401/10 ,  C09K11/06 ,  H10K50/125 ,  H10K85/322 ,  H10K85/654 ,  H10K85/6572 ,  C09K2211/1018 ,  H10K2101/10 ,  H10K2101/27 ,  H10K2101/30 ,  H10K2101/90

Abstract: A hybrid emissive layer and OLED incorporating the same are provided. The hybrid emissive layer includes a first material having a triplet state energy level T1H and a singlet state energy level S1H, & second material having a triplet state energy level T1F and a singlet state energy level S1F; and a third material having a triplet state energy level T1P and a single state energy level S1P, where T1F≥T1H; S1F≤S1H; and T1P

公开(公告)号：US20240317729A1

公开(公告)日：2024-09-26

申请号：US18667078

申请日：2024-05-17

Applicant: YALE UNIVERSITY ,  GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  CAMBRIDGE ENTERPRISE LIMITED

Inventor： CRAIG M. CREWS ,  DENNIS BUCKLEY ,  ALESSIO CIULLI ,  WILLIAM L. JORGENSEN ,  PETER C. GAREISS ,  INGE VAN MOLLE ,  JEFFREY GUSTAFSON ,  HYUN-SEOP TAE ,  JULIEN MICHEL ,  DENTON WADE HOYER ,  ANKE G. ROTH ,  JOHN DAVID HARLING ,  IAN EDWARD DAVID SMITH ,  AFJAL HUSSAIN MIAH ,  SEBASTIEN ANDRE CAMPOS ,  JOELLE LE

IPC: C07D413/14 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61K38/05 ,  A61K38/06 ,  A61K45/06 ,  A61K47/54 ,  A61K47/55 ,  A61K47/64 ,  C07D207/16 ,  C07D207/26 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07J43/00 ,  C12N9/00

CPC classification number: C07D413/14 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/5377 ,  A61K38/05 ,  A61K38/06 ,  A61K45/06 ,  A61K47/545 ,  A61K47/55 ,  A61K47/64 ,  C07D207/16 ,  C07D207/26 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D405/06 ,  C07D405/12 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07J43/003 ,  C12N9/93

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

公开(公告)号：US20240294494A1

公开(公告)日：2024-09-05

申请号：US18407053

申请日：2024-01-08

Applicant: BioCryst Pharmaceuticals, Inc

Inventor： Pravin L. Kotian ,  Yarlagadda S. Babu ,  Weihe Zhang ,  Peng-Cheng Lu ,  Minwan Wu ,  Wei Lv ,  Trung Xuan Nguyen ,  Zhao Dang ,  Venkat R. Chintareddy ,  V. Satish Kumar ,  Krishnan Raman

IPC: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

CPC classification number: C07D401/10 ,  C07D209/12 ,  C07D261/20 ,  C07D307/80 ,  C07D333/64 ,  C07D401/12 ,  C07D405/10

Abstract: Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

公开(公告)号：US12082500B2

公开(公告)日：2024-09-03

申请号：US15371066

申请日：2016-12-06

Applicant: Samsung Display Co., Ltd

Inventor： Junha Park ,  Youngkook Kim ,  Munki Sim ,  Eunyoung Lee ,  Hyoyoung Lee ,  Eunjae Jeong ,  Seokhwan Hwang

IPC: H10K85/60 ,  C07D221/18 ,  C07D401/10 ,  C07D405/10 ,  C07D471/04 ,  C07F9/576 ,  C07F9/6558 ,  C07F9/6561 ,  H10K50/16 ,  H10K50/17 ,  H10K50/18

CPC classification number: H10K85/6572 ,  C07D221/18 ,  C07D401/10 ,  C07D405/10 ,  C07D471/04 ,  C07F9/5765 ,  C07F9/65583 ,  C07F9/6561 ,  H10K85/626 ,  H10K85/654 ,  H10K85/6574 ,  H10K50/16 ,  H10K50/171 ,  H10K50/18

Abstract: Provided are a condensed cyclic compound and an organic light-emitting device. The condensed cyclic compound is represented by Formula 1:




Details about the constituents of Formula 1 is disclosed.

公开(公告)号：US20240287023A1

公开(公告)日：2024-08-29

申请号：US18634587

申请日：2024-04-12

Applicant: Kura Oncology, Inc.

Inventor： Xuefeng Zhu ,  Pingda Ren ,  Zhu Bai ,  Wanting Xiong ,  Dan Xu ,  Yahu Arthur Liu

IPC: C07D401/10 ,  A61P35/00 ,  C07D491/044

CPC classification number: C07D401/10 ,  A61P35/00 ,  C07D491/044

Abstract: The present invention relates to macrocyclic compounds of any one of Formula (I), or a pharmaceutically acceptable form thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating cancer dependent on a farnesylated protein, using the same.

公开(公告)号：US12071424B2

公开(公告)日：2024-08-27

申请号：US18176362

申请日：2023-02-28

Applicant: Cornell University

Inventor： Joseph P. Vacca ,  Dansu Li ,  Sarah Elizabeth Bettigole

IPC: C07D401/04 ,  A61K31/517 ,  A61P35/00 ,  C07D217/22 ,  C07D239/74 ,  C07D239/84 ,  C07D239/94 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07D401/10 ,  A61P35/00 ,  C07D217/22 ,  C07D239/84 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D413/04 ,  C07D417/04

Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.

公开(公告)号：US12069879B2

公开(公告)日：2024-08-20

申请号：US16161574

申请日：2018-10-16

Applicant: Samsung Electronics Co., Ltd. ,  Samsung SDI Co., Ltd.

Inventor： Jongsoo Kim ,  Joonghyuk Kim ,  Namheon Lee ,  Inkoo Kim ,  Daun Jeong ,  Sunghan Kim ,  Myungsun Sim ,  Sooghang Ihn

IPC: H10K50/805 ,  C07D209/82 ,  C07D219/14 ,  C07D333/76 ,  C07D401/10 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/10 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  H10K50/12 ,  H10K50/13 ,  H10K50/16 ,  H10K85/30 ,  H10K85/40 ,  H10K85/60 ,  H10K101/00

CPC classification number: H10K50/805 ,  C07D209/82 ,  C07D219/14 ,  C07D333/76 ,  C07D401/10 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/10 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  H10K50/13 ,  H10K50/16 ,  H10K85/342 ,  H10K85/40 ,  H10K85/654 ,  H10K85/657 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576 ,  H10K50/12 ,  H10K2101/90

Abstract: An organic light-emitting device including a first electrode, a second electrode facing the first electrode, and an emission layer disposed between the first electrode and the second electrode, wherein the emission layer includes a first material not including an electron transport moiety, a second material including at least one electron transport moiety, a third material having reorganization energy of about 0.4 eV or more, and a light-emitting material, wherein the first material, the second material, the third material, and the light-emitting material are different from one another, and wherein a ratio of a light-emitting component emitted from the light-emitting material to a total of light-emitting components emitted from the emission layer is about 90% or more.

公开(公告)号：US12053462B2

公开(公告)日：2024-08-06

申请号：US17379175

申请日：2021-07-19

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Taryn Campbell ,  Jayaraman Chandrasekhar ,  Christopher T. Clark ,  Julian A. Codelli ,  Kevin S. Currie ,  Jeffrey E. Kropf ,  Yasamin Moazami ,  Nicole Nava ,  Leena Patel ,  Stephane Perreault ,  Jason K. Perry ,  Kassandra F. Sedillo ,  Natalie Seeger ,  Kirk L. Stevens ,  Jennifer Anne Treiberg ,  Suet C. Yeung ,  Zhongdong Zhao

IPC: C07D215/02 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5355 ,  A61K31/541 ,  A61K45/06 ,  C07D215/14 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D215/18 ,  C07D401/04 ,  C07D413/04 ,  C07D417/14 ,  C07D475/02 ,  C07D491/04 ,  C07D491/06 ,  C07D491/08 ,  C07D498/10 ,  C07D513/04

CPC classification number: A61K31/47 ,  A61K31/4375 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5355 ,  A61K31/541 ,  A61K45/06 ,  C07D215/14 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D215/18 ,  C07D401/04 ,  C07D413/04 ,  C07D417/14 ,  C07D475/02 ,  C07D491/04 ,  C07D491/06 ,  C07D491/08 ,  C07D498/10 ,  C07D513/04

Abstract: The present disclosure provides a compound of Formula (I):




or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.